Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

IMA new masthead1

Internal Medicine Alert – April 30, 2024

April 30, 2024

View Archives Issues

  • Doxycycline Reduces the Risk of C. difficile Infection in Patients Treated for CAP

    In a retrospective study from the VA, doxycycline was associated with a lower risk of C. difficile infection compared to azithromycin in hospitalized patients with community-acquired pneumonia.

  • Can Bariatric Surgery Control Blood Pressure Long-Term?

    A randomized trial comparing bariatric surgery to medical therapy in hypertensive obese patients has shown that bariatric surgery effectively lowers blood pressure over five years of follow-up.

  • Food as Medicine? Follow the Evidence

    In this randomized, controlled study of more than 400 individuals with uncontrolled type 2 diabetes and food insecurity, an intensive intervention offering healthy groceries and educational efforts failed to significantly affect glycemic control but resulted in heightened engagement with preventive healthcare services in the intervention group compared to the control.

  • Quality, not Quantity: Plant-Based Carbs Might Result in Less Weight Gain

    This long-term prospective study found that adults on low-carbohydrate diets rich in plant-based and whole grain sources of protein and fat experienced significantly less weight gain than those on other types of low-carbohydrate diets.

  • Resmetirom Tablets (Rezdiffra)

    The U.S. Food and Drug Administration has approved the first drug and first-in-class for the treatment of metabolic dysfunction-associated steatohepatitis (formerly known as nonalcoholic steatohepatitis). Resmetirom is a selective thyroid hormone receptor-beta partial agonist and was granted an accelerated approval. It is distributed by Madrigal Pharmaceuticals, Inc. as Rezdiffra.